Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 285 TWD -1.72% Market Closed
Market Cap: 75.6B TWD
Have any thoughts about
Lotus Pharmaceutical Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Lotus Pharmaceutical Co Ltd stock under the Base Case scenario is 364.33 TWD. Compared to the current market price of 285 TWD, Lotus Pharmaceutical Co Ltd is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
364.33 TWD
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lotus Pharmaceutical Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Lotus Pharmaceutical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Lotus Pharmaceutical Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Lotus Pharmaceutical Co Ltd

Provide an overview of the primary business activities
of Lotus Pharmaceutical Co Ltd.

What unique competitive advantages
does Lotus Pharmaceutical Co Ltd hold over its rivals?

What risks and challenges
does Lotus Pharmaceutical Co Ltd face in the near future?

Summarize the latest earnings call
of Lotus Pharmaceutical Co Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lotus Pharmaceutical Co Ltd.

Provide P/S
for Lotus Pharmaceutical Co Ltd.

Provide P/E
for Lotus Pharmaceutical Co Ltd.

Provide P/OCF
for Lotus Pharmaceutical Co Ltd.

Provide P/FCFE
for Lotus Pharmaceutical Co Ltd.

Provide P/B
for Lotus Pharmaceutical Co Ltd.

Provide EV/S
for Lotus Pharmaceutical Co Ltd.

Provide EV/GP
for Lotus Pharmaceutical Co Ltd.

Provide EV/EBITDA
for Lotus Pharmaceutical Co Ltd.

Provide EV/EBIT
for Lotus Pharmaceutical Co Ltd.

Provide EV/OCF
for Lotus Pharmaceutical Co Ltd.

Provide EV/FCFF
for Lotus Pharmaceutical Co Ltd.

Provide EV/IC
for Lotus Pharmaceutical Co Ltd.

Show me price targets
for Lotus Pharmaceutical Co Ltd made by professional analysts.

What are the Revenue projections
for Lotus Pharmaceutical Co Ltd?

How accurate were the past Revenue estimates
for Lotus Pharmaceutical Co Ltd?

What are the Net Income projections
for Lotus Pharmaceutical Co Ltd?

How accurate were the past Net Income estimates
for Lotus Pharmaceutical Co Ltd?

What are the EPS projections
for Lotus Pharmaceutical Co Ltd?

How accurate were the past EPS estimates
for Lotus Pharmaceutical Co Ltd?

What are the EBIT projections
for Lotus Pharmaceutical Co Ltd?

How accurate were the past EBIT estimates
for Lotus Pharmaceutical Co Ltd?

Compare the revenue forecasts
for Lotus Pharmaceutical Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lotus Pharmaceutical Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lotus Pharmaceutical Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lotus Pharmaceutical Co Ltd compared to its peers.

Compare the P/E ratios
of Lotus Pharmaceutical Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Lotus Pharmaceutical Co Ltd with its peers.

Analyze the financial leverage
of Lotus Pharmaceutical Co Ltd compared to its main competitors.

Show all profitability ratios
for Lotus Pharmaceutical Co Ltd.

Provide ROE
for Lotus Pharmaceutical Co Ltd.

Provide ROA
for Lotus Pharmaceutical Co Ltd.

Provide ROIC
for Lotus Pharmaceutical Co Ltd.

Provide ROCE
for Lotus Pharmaceutical Co Ltd.

Provide Gross Margin
for Lotus Pharmaceutical Co Ltd.

Provide Operating Margin
for Lotus Pharmaceutical Co Ltd.

Provide Net Margin
for Lotus Pharmaceutical Co Ltd.

Provide FCF Margin
for Lotus Pharmaceutical Co Ltd.

Show all solvency ratios
for Lotus Pharmaceutical Co Ltd.

Provide D/E Ratio
for Lotus Pharmaceutical Co Ltd.

Provide D/A Ratio
for Lotus Pharmaceutical Co Ltd.

Provide Interest Coverage Ratio
for Lotus Pharmaceutical Co Ltd.

Provide Altman Z-Score Ratio
for Lotus Pharmaceutical Co Ltd.

Provide Quick Ratio
for Lotus Pharmaceutical Co Ltd.

Provide Current Ratio
for Lotus Pharmaceutical Co Ltd.

Provide Cash Ratio
for Lotus Pharmaceutical Co Ltd.

What is the historical Revenue growth
over the last 5 years for Lotus Pharmaceutical Co Ltd?

What is the historical Net Income growth
over the last 5 years for Lotus Pharmaceutical Co Ltd?

What is the current Free Cash Flow
of Lotus Pharmaceutical Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lotus Pharmaceutical Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lotus Pharmaceutical Co Ltd

Current Assets 13.7B
Cash & Short-Term Investments 3.1B
Receivables 6.4B
Other Current Assets 4.3B
Non-Current Assets 20.6B
Long-Term Investments 3.1B
PP&E 3.6B
Intangibles 13.1B
Other Non-Current Assets 756m
Current Liabilities 6B
Accounts Payable 696.9m
Short-Term Debt 557.5m
Other Current Liabilities 4.8B
Non-Current Liabilities 11.1B
Long-Term Debt 9.6B
Other Non-Current Liabilities 1.5B
Efficiency

Earnings Waterfall
Lotus Pharmaceutical Co Ltd

Revenue
16.9B TWD
Cost of Revenue
-7.7B TWD
Gross Profit
9.3B TWD
Operating Expenses
-4.7B TWD
Operating Income
4.5B TWD
Other Expenses
-500.6m TWD
Net Income
4B TWD

Free Cash Flow Analysis
Lotus Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q1 2024, the company saw a 7% decline in consolidated revenue to TWD 4.2 billion, primarily due to lower U.S. sales from timing issues and increased competition. Gross margin remained steady at 55%, but net profits were TWD 1.04 billion. Key growth markets were Korea and Taiwan, with significant gains in specific brands like Qsymia and Cialis. The company continues to focus on expanding its product portfolio and strategic M&A opportunities in Southeast Asia, aiming for double-digit growth. Full-year revenue from lenalidomide is expected to peak in Q2 and Q3 with potential replenishments in Q4.

What is Earnings Call?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Lotus Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Operating Income
Positive ROE
59/100
Profitability
Score

Lotus Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Lotus Pharmaceutical Co Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
62/100
Solvency
Score

Lotus Pharmaceutical Co Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Lotus Pharmaceutical Co Ltd

Wall Street analysts forecast Lotus Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Lotus Pharmaceutical Co Ltd is 443.7 TWD with a low forecast of 338.35 TWD and a high forecast of 630 TWD.

Lowest
Price Target
338.35 TWD
19% Upside
Average
Price Target
443.7 TWD
56% Upside
Highest
Price Target
630 TWD
121% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Lotus Pharmaceutical Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Lotus Pharmaceutical Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd

Country

Taiwan

Industry

Pharmaceuticals

Market Cap

75.4B TWD

Dividend Yield

0%

Description

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of generic pharmaceutical products; and the provision of consulting services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-12-13. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The firm is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The firm mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Contact

TAIPEI
Taipei City
17F, No. 277, Songren Road, Xinyi District
+886227005908
www.lotuspharm.com.tw

IPO

2004-12-13

Employees

-

Officers

CEO & Director
Mr. Petar Antonov Vazharov
Vice President of Supply Chain & Operations
Mr. Zenon Zdunek
Chief Financial Officer
Ms. Eeling Chan
Chief Information Officer
Ms. Gwen Hsieh
Associate Director of Co-Operate Communication
Ms. Yu-Ying Yang
Deputy General Manager
Boon Chong Tan
Show More
Vice President
Yingming Yue
Chief Commercial Officer-APAC
Valerie Lau
Vice President of Research and Development
Mr. Manish Chawla
Show Less

See Also

Discover More
What is the Intrinsic Value of one Lotus Pharmaceutical Co Ltd stock?

The intrinsic value of one Lotus Pharmaceutical Co Ltd stock under the Base Case scenario is 364.33 TWD.

Is Lotus Pharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 285 TWD, Lotus Pharmaceutical Co Ltd is Undervalued by 22%.

Back to Top